Most uterine cancer is endometrial cancer — arising from the lining cells of the uterus. A small but important subset (3–7%) is uterine sarcoma, arising from the muscle wall or supporting tissues. The distinction matters because sarcoma behaves differently, responds to different treatments, and has different prognosis.
On this page
- What each cancer actually is
- Types of uterine sarcoma
- Symptoms — how they overlap
- Why diagnosis is tricky
- Treatment differences
- Prognosis
Uterine sarcoma vs endometrial cancer — What each cancer actually is
Endometrial cancer arises from the endometrium — the inner lining cells of the uterus. Hormonally driven, strongly linked to obesity and unopposed estrogen exposure.
Uterine sarcoma arises from the muscle wall (myometrium) or supporting connective tissue. Not hormonally driven in the same way; not associated with the same risk factors.
Types of uterine sarcoma
- Leiomyosarcoma — most common, arises from smooth muscle
- Endometrial stromal sarcoma — arises from supporting stromal cells
- Carcinosarcoma (Malignant Mixed Mullerian Tumour) — historically classified as sarcoma but now treated as an aggressive endometrial cancer variant
- Undifferentiated sarcoma — rare, aggressive
Symptoms — how they overlap
Both can present with abnormal uterine bleeding. Differences in presentation:
- Sarcoma more likely in slightly younger women (perimenopausal)
- Sarcoma often presents with rapidly enlarging uterine mass
- Sarcoma may cause pain (myometrial expansion)
- Endometrial cancer is more likely to present purely with bleeding
Why diagnosis is tricky
Office endometrial biopsy reliably samples the lining — diagnosing endometrial cancer. But it does NOT reliably sample the muscle wall — meaning sarcomas can be missed pre-operatively and only diagnosed on final histopathology after hysterectomy. This is why apparent fibroids that grow rapidly in perimenopausal or postmenopausal women warrant cancer-aware surgical planning.
Treatment differences
- Both treated primarily with surgery (hysterectomy + bilateral salpingo-oophorectomy)
- Endometrial cancer: adjuvant radiation +/- chemotherapy based on risk factors
- Sarcoma: adjuvant chemotherapy more commonly considered; radiation less effective
- Sarcoma may use specific chemotherapy regimens (doxorubicin-based)
- Sarcoma should not be morcellated (cutting into pieces during minimally invasive surgery) — this can spread disease
Prognosis
Uterine sarcomas are aggressive — even Stage 1 leiomyosarcoma has higher recurrence and lower 5-year survival than Stage 1 endometrial cancer. Why specialist surgical and oncological management matters from the start.
See uterine cancer page for full disease detail.
FAQs
I have fibroids — how do I know they're not sarcoma?
Most fibroids are benign. Concerning signs include: rapid growth in postmenopausal women, atypical features on MRI, persistent unexplained pain. If concerning, a specialist gynaec-onco consultation is appropriate.
Can sarcoma be diagnosed before surgery?
Sometimes — atypical features on MRI, abnormal endometrial biopsy, or core needle biopsy under imaging guidance. But many sarcomas are diagnosed only on post-surgical pathology.
Why is morcellation avoided?
Cutting a presumed fibroid into pieces during laparoscopic removal can spread occult sarcoma cells across the abdomen, worsening prognosis. FDA issued warnings on this. We avoid morcellation in suspicious cases.
What is the role of chemotherapy?
More commonly used for sarcoma than for early endometrial cancer. Specific regimens (doxorubicin, ifosfamide, gemcitabine-docetaxel) are used.
Can sarcoma be cured?
Stage 1 with complete resection has cure rates of 40-60% for leiomyosarcoma — lower than endometrial cancer. Aggressive surveillance and prompt treatment of recurrence are essential.
Consultation and Next Steps
For an individualised consultation on uterine sarcoma vs endometrial cancer, share your reports on WhatsApp at +91 76988 00333. Dr. Nishtha Tripathi Patel provides a detailed assessment within 24-48 hours and arranges in-person consultation at Sterling Hospitals, KD Hospital, or Welcare Speciality Hospital in Ahmedabad based on your location and treatment requirements.
Bring the following to your first consultation: imaging studies (ultrasound, CT or MRI on CD), histopathology and biopsy reports, tumour marker results (CA-125, HE4, CEA where relevant), a list of current medications, and any prior treatment summaries. For patients travelling from outside Ahmedabad, scheduling can be arranged to complete consultation and any pre-op work-up in the fewest possible visits.
If you are exploring second-opinion options, see our second-opinion service page. Independent review of diagnosis, staging, and proposed treatment plans is provided at no cost via WhatsApp report review. You do not need to switch hospitals to obtain a second opinion.
For broader information about uterine sarcoma vs endometrial cancer and related conditions, also see our complete ovarian cancer guide, HIPEC India guide, cervical cancer guide and robotic surgery guide.
Reviewed by Dr. Nishtha Tripathi Patel, MBBS, DGO, DNB, Fellowship Gynaecological Oncology, ESGO-certified. To book: WhatsApp +91 76988 00333.